Linked Data API

Show Search Form

Search Results

1130447
star this property human indexable true more like this
star this property published true more like this
star this property registered interest false more like this
star this property answer date less than 2019-06-10more like thismore than 2019-06-10
star this property date less than 2019-06-06more like thismore than 2019-06-06
star this property date tabled less than 2019-06-06more like thismore than 2019-06-06
star this property ddp created less than 2019-06-06T16:59:01.330Zmore like thismore than 2019-06-06T16:59:01.330Z
star this property answering body
Department for International Trade more like this
star this property question status Tabled more like this
star this property answering dept id 202 more like this
unstar this property answering dept short name International Trade more like this
star this property answering dept sort name International Trade more like this
star this property ddp modified
less than 2019-06-10T19:15:06.237Zmore like thismore than 2019-06-10T19:15:06.237Z
less than 2019-06-14T13:47:03.189Zmore like thismore than 2019-06-14T13:47:03.189Z
star this property hansard heading Financial Services: Foreign Investment in UK more like this
star this property house id 1 more like this
star this property identifier 261177 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property parliament number 57 more like this
star this property question first answered
less than 2019-06-14T13:15:37.327Zmore like thismore than 2019-06-14T13:15:37.327Z
star this property question text To ask the Secretary of State for International Trade, what assessment he has made of recent trends of the level of foreign direct investment into the UK FinTech industry in the (a) 2017-18 and (b) 2016-17 financial years. more like this
star this property session
2017/19 more like this
star this property session number 1 more like this
star this property tabling member constituency Windsor more like this
star this property tabling member printed
Adam Afriyie more like this
star this property title House of Commons Tabled Parliamentary Question 2017/19 261177 more like this
star this property type
WrittenParliamentaryQuestion
star this property uin 261177 more like this
star this property version 2 more like this
star this property written parliamentary question type Ordinary more like this
star this property answer
answer
unstar this property answer text <p>The information regarding FDI is not held centrally and could only be obtained at disproportionate cost.</p><p> </p><p>Last year British FinTech’s attracted more venture capital funding than any other European country once again totalling $1.73 billion across 261 deals.</p> more like this
star this property creator
1586
star this property label Biography information for Adam Afriyie more like this
star this property publisher
25259
star this property pref label House of Commons more like this
star this property tabling member
1586
unstar this property label Biography information for Adam Afriyie more like this
1130448
star this property human indexable true more like this
star this property published true more like this
star this property registered interest false more like this
star this property answer date less than 2019-06-10more like thismore than 2019-06-10
star this property date less than 2019-06-06more like thismore than 2019-06-06
star this property date tabled less than 2019-06-06more like thismore than 2019-06-06
star this property ddp created less than 2019-06-06T16:59:04.470Zmore like thismore than 2019-06-06T16:59:04.470Z
star this property answering body
Treasury more like this
star this property question status Tabled more like this
star this property answering dept id 14 more like this
unstar this property answering dept short name Treasury more like this
star this property answering dept sort name Treasury more like this
star this property ddp modified
less than 2019-06-06T17:08:48.668Zmore like thismore than 2019-06-06T17:08:48.668Z
less than 2019-06-14T08:18:01.865Zmore like thismore than 2019-06-14T08:18:01.865Z
star this property hansard heading Financial Services: Taxation more like this
star this property house id 1 more like this
star this property identifier 261178 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property parliament number 57 more like this
star this property question first answered
less than 2019-06-14T07:46:18.553Zmore like thismore than 2019-06-14T07:46:18.553Z
star this property question text To ask the Chancellor of the Exchequer, how much the UK FinTech industry paid the Exchequer in tax revenue in (a) 2017-18 and (b) 2016-17 financial years. more like this
star this property session
2017/19 more like this
star this property session number 1 more like this
star this property tabling member constituency Windsor more like this
star this property tabling member printed
Adam Afriyie more like this
star this property title House of Commons Tabled Parliamentary Question 2017/19 261178 more like this
star this property type
WrittenParliamentaryQuestion
star this property uin 261178 more like this
star this property version 1 more like this
star this property written parliamentary question type Ordinary more like this
star this property answer
answer
unstar this property answer text <p>HM Revenue and Customs (HMRC) publishes annual statistics relating to income tax, VAT and corporation tax by industry (including the Financial and Insurance Activities Sector). However, HMRC cannot identify receipts from the UK FinTech industry specifically.</p><p> </p><p>For other taxes, industry-level information is not available.</p><p> </p><p>For business rates, the Ministry of Housing, Communities &amp; Local Government collects data only at local authority level and is unable to provide a breakdown by industry.</p> more like this
star this property creator
1586
star this property label Biography information for Adam Afriyie more like this
star this property publisher
25259
star this property pref label House of Commons more like this
star this property tabling member
1586
unstar this property label Biography information for Adam Afriyie more like this
1130450
star this property human indexable true more like this
star this property published true more like this
star this property registered interest false more like this
star this property answer date less than 2019-06-10more like thismore than 2019-06-10
star this property date less than 2019-06-06more like thismore than 2019-06-06
star this property date tabled less than 2019-06-06more like thismore than 2019-06-06
star this property ddp created less than 2019-06-06T16:59:09.727Zmore like thismore than 2019-06-06T16:59:09.727Z
star this property answering body
Treasury more like this
star this property question status Tabled more like this
star this property answering dept id 14 more like this
unstar this property answering dept short name Treasury more like this
star this property answering dept sort name Treasury more like this
star this property ddp modified
less than 2019-06-06T17:09:47.759Zmore like thismore than 2019-06-06T17:09:47.759Z
less than 2019-06-13T14:12:01.893Zmore like thismore than 2019-06-13T14:12:01.893Z
star this property hansard heading Cryptocurrencies more like this
star this property house id 1 more like this
star this property identifier 261180 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property parliament number 57 more like this
star this property question first answered
less than 2019-06-13T13:40:32.78Zmore like thisremove minimum value filter
star this property question text To ask the Chancellor of the Exchequer, what recent assessment the Government has made of the potential merits of cryptocurrencies as a means of payment. more like this
star this property session
2017/19 more like this
star this property session number 1 more like this
star this property tabling member constituency Windsor more like this
star this property tabling member printed
Adam Afriyie more like this
star this property title House of Commons Tabled Parliamentary Question 2017/19 261180 more like this
star this property type
WrittenParliamentaryQuestion
star this property uin 261180 more like this
star this property version 1 more like this
star this property written parliamentary question type Ordinary more like this
star this property answer
answer
unstar this property answer text The Government established the Cryptoassets Taskforce – comprised of HM Treasury, the Financial Conduct Authority and the Bank of England – in 2018 to explore the risks and potential benefits of cryptoassets and the underlying distributed ledger technology (DLT). The Taskforce’s final report<sup><sup>[1]</sup></sup> concluded that benefits associated with the use of cryptoassets may arise in the future, but that the most immediate priorities for the authorities are to mitigate the risks posed by cryptoassets to consumers and markets, and to prevent the use of cryptoassets for illicit activity. As part of this, the Government will consult on its approach to cryptoassets this year. In addition, the authorities continue to encourage the responsible development of legitimate DLT and cryptoasset-related activity in the UK.<p> </p><p>[1] Full version of the report is available at: <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/752070/cryptoassets_taskforce_final_report_final_web.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/752070/cryptoassets_taskforce_final_report_final_web.pdf</a></p>
star this property creator
1586
star this property label Biography information for Adam Afriyie more like this
star this property publisher
25259
star this property pref label House of Commons more like this
star this property tabling member
1586
unstar this property label Biography information for Adam Afriyie more like this
1130540
star this property human indexable true more like this
star this property published true more like this
star this property registered interest false more like this
star this property answer date less than 2019-06-10more like thismore than 2019-06-10
star this property date less than 2019-06-06more like thismore than 2019-06-06
star this property date tabled less than 2019-06-06more like thismore than 2019-06-06
star this property ddp created less than 2019-06-06T17:02:50.233Zmore like thismore than 2019-06-06T17:02:50.233Z
star this property answering body
Department for Environment, Food and Rural Affairs more like this
star this property question status Tabled more like this
star this property answering dept id 13 more like this
unstar this property answering dept short name Environment, Food and Rural Affairs more like this
star this property answering dept sort name Environment, Food and Rural Affairs more like this
star this property ddp modified
less than 2019-06-06T17:13:48.971Zmore like thismore than 2019-06-06T17:13:48.971Z
less than 2019-06-14T11:40:02.296Zmore like thismore than 2019-06-14T11:40:02.296Z
star this property hansard heading Biodiversity more like this
star this property house id 1 more like this
star this property identifier 261183 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property parliament number 57 more like this
star this property question first answered
less than 2019-06-14T11:08:13.313Zmore like thismore than 2019-06-14T11:08:13.313Z
star this property question text To ask the Secretary of State for Environment, Food and Rural Affairs, whether he has made an assessment of the contribution that green bridges make to biodiversity. more like this
star this property session
2017/19 more like this
star this property session number 1 more like this
star this property tabling member constituency Windsor more like this
star this property tabling member printed
Adam Afriyie more like this
star this property title House of Commons Tabled Parliamentary Question 2017/19 261183 more like this
star this property type
WrittenParliamentaryQuestion
star this property uin 261183 more like this
star this property version 1 more like this
star this property written parliamentary question type Ordinary more like this
star this property answer
answer
unstar this property answer text <p>Green bridges are structures designed to provide wildlife and non-motorised users with easy and safe crossing of main roads and railways.</p><p> </p><p>In 2015, Natural England published a review of the literature on green bridges. The review looked at 53 case studies from Europe and North America and found evidence that, in the majority of cases, green bridges were utilised by wildlife, although an assessment of their effectiveness in conserving wildlife populations was limited by the lack of long-term monitoring data. Guidance on the design of green bridges was also published by the Landscape Institute based on research undertaken by Natural England.</p><p> </p><p>In 2015, the Government published research which included an assessment of the A21 Scotney Caste Green Bridge, constructed by the then Highways Agency, which found that of all incidences of bats crossing the road to and from the Scotney Castle Estate, 97 per cent used the green bridge. At least five bat species were recorded foraging over the bridge which was also used by deer, badger and breeding dormice.</p><p> </p><p>The Government will keep the evidence for the effectiveness of these structures under review as new green bridges are planned and implemented.</p>
star this property creator
1586
star this property label Biography information for Adam Afriyie more like this
star this property publisher
25259
star this property pref label House of Commons more like this
star this property tabling member
1586
unstar this property label Biography information for Adam Afriyie more like this
1130541
star this property human indexable true more like this
star this property published true more like this
star this property registered interest false more like this
star this property answer date less than 2019-06-10more like thismore than 2019-06-10
star this property date less than 2019-06-06more like thismore than 2019-06-06
star this property date tabled less than 2019-06-06more like thismore than 2019-06-06
star this property ddp created less than 2019-06-06T17:02:52.517Zmore like thismore than 2019-06-06T17:02:52.517Z
star this property answering body
Department for Environment, Food and Rural Affairs more like this
star this property question status Tabled more like this
star this property answering dept id 13 more like this
unstar this property answering dept short name Environment, Food and Rural Affairs more like this
star this property answering dept sort name Environment, Food and Rural Affairs more like this
star this property ddp modified
less than 2019-06-06T17:13:51.190Zmore like thismore than 2019-06-06T17:13:51.190Z
less than 2019-06-14T10:24:01.554Zmore like thismore than 2019-06-14T10:24:01.554Z
star this property hansard heading Biodiversity more like this
star this property house id 1 more like this
star this property identifier 261184 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property parliament number 57 more like this
star this property question first answered
less than 2019-06-14T09:52:58.77Zmore like thismore than 2019-06-14T09:52:58.77Z
star this property question text To ask the Secretary of State for Environment, Food and Rural Affairs, which key performance indicators his Department uses to assess progress in improving the UK’s biodiversity. more like this
star this property session
2017/19 more like this
star this property session number 1 more like this
star this property tabling member constituency Windsor more like this
star this property tabling member printed
Adam Afriyie more like this
star this property title House of Commons Tabled Parliamentary Question 2017/19 261184 more like this
star this property type
WrittenParliamentaryQuestion
star this property uin 261184 more like this
star this property version 1 more like this
star this property written parliamentary question type Ordinary more like this
star this property answer
answer
unstar this property answer text <p>Domestic biodiversity policy is a devolved matter. The UK government has a range of performance indicators for England, although we do also work with the devolved administrations to compile indicators at UK scale for international reporting.</p><p> </p><p>In June 2019 the Department for Environment, Food and Rural Affairs published its <a href="https://www.gov.uk/government/publications/department-for-environment-food-and-rural-affairs-single-departmental-plan/department-for-environment-food-and-rural-affairs-single-departmental-plan-may-2018" target="_blank">Single Departmental Plan</a> which includes biodiversity performance indicators for England, including: extent of marine protected areas and condition of protected sites and priority habitat.</p><p> </p><p>In May of this year, the Government published a <a href="https://www.gov.uk/government/publications/25-year-environment-plan" target="_blank">new indicator framework</a> for the 25 Year Environment Plan, setting out a transparent, comprehensive framework that shows how the environment in England is changing and whether it is improving over time. These indicators include diversity and health of our seas, wildlife and wild places, and nature on land and water.</p><p> </p><p>To support reporting of progress across the whole of the UK, the government publishes a set of <a href="https://www.gov.uk/government/statistics/biodiversity-indicators-for-the-uk" target="_blank">UK Biodiversity Indicators,</a> updated annually. These measure long term trends in the UK’s biodiversity and progress against our international commitments under the Convention on Biological Diversity.</p>
star this property creator
1586
star this property label Biography information for Adam Afriyie more like this
star this property publisher
25259
star this property pref label House of Commons more like this
star this property tabling member
1586
unstar this property label Biography information for Adam Afriyie more like this
1141362
star this property human indexable true more like this
star this property published true more like this
star this property registered interest false more like this
star this property answer date less than 2019-07-25more like thismore than 2019-07-25
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property date tabled less than 2019-07-23more like thismore than 2019-07-23
star this property ddp created less than 2019-07-23T16:59:17.467Zmore like thismore than 2019-07-23T16:59:17.467Z
star this property answering body
Department of Health and Social Care more like this
star this property question status Tabled more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property ddp modified
less than 2019-07-24T15:15:31.088Zmore like thismore than 2019-07-24T15:15:31.088Z
less than 2019-08-05T12:04:07.710Zmore like thismore than 2019-08-05T12:04:07.710Z
star this property hansard heading Measles more like this
star this property house id 1 more like this
star this property identifier 280995 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property parliament number 57 more like this
star this property question first answered
less than 2019-08-05T11:32:33.127Zmore like thismore than 2019-08-05T11:32:33.127Z
star this property question text To ask the Secretary of State for Health and Social Care, what guidance his Department has published on distinguishing between rashes caused by the measles vaccine and those arising from the wild strain of measles. more like this
star this property session
2017/19 more like this
star this property session number 1 more like this
star this property tabling member constituency Gravesham more like this
star this property tabling member printed
Adam Holloway more like this
star this property title House of Commons Tabled Parliamentary Question 2017/19 280995 more like this
star this property type
WrittenParliamentaryQuestion
star this property uin 280995 more like this
star this property version 2 more like this
star this property written parliamentary question type Ordinary more like this
star this property answer
answer
unstar this property answer text <p>While post vaccine rash and fever is generally mild, distinguishing from wild-type measles is not based on clinical examination, rather it is based on a combination of laboratory analysis, information on the timing of vaccine and epidemiological information. The national measles guidelines describe the management and investigation of suspected cases of measles, and is available to view at the following link:</p><p><a href="https://www.gov.uk/government/publications/national-measles-guidelines" target="_blank">https://www.gov.uk/government/publications/national-measles-guidelines</a></p><p>Statistics on confirmed measles cases are reported by vaccination status and are available at the following link:</p><p><a href="https://www.gov.uk/government/publications/measles-mumps-and-rubella-lab-confirmed-cases-in-england-2019" target="_blank">https://www.gov.uk/government/publications/measles-mumps-and-rubella-lab-confirmed-cases-in-england-2019</a></p><p> </p><p> </p> more like this
star this property creator
1522
star this property label Biography information for Adam Holloway more like this
star this property publisher
25259
star this property pref label House of Commons more like this
star this property tabling member
1522
unstar this property label Biography information for Adam Holloway more like this
1141363
star this property human indexable true more like this
star this property published true more like this
star this property registered interest false more like this
star this property answer date less than 2019-07-25more like thismore than 2019-07-25
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property date tabled less than 2019-07-23more like thismore than 2019-07-23
star this property ddp created less than 2019-07-23T16:59:19.817Zmore like thismore than 2019-07-23T16:59:19.817Z
star this property answering body
Department of Health and Social Care more like this
star this property question status Tabled more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property ddp modified
less than 2019-07-23T17:09:26.136Zmore like thismore than 2019-07-23T17:09:26.136Z
less than 2019-08-05T12:04:06.112Zmore like thismore than 2019-08-05T12:04:06.112Z
star this property hansard heading Measles more like this
star this property house id 1 more like this
star this property identifier 280996 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property parliament number 57 more like this
star this property question first answered
less than 2019-08-05T11:32:33.183Zmore like thismore than 2019-08-05T11:32:33.183Z
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that statistics on the infection rate for measles do not include people who have received the live measles vaccine and contracted a measles-like rash and fever. more like this
star this property session
2017/19 more like this
star this property session number 1 more like this
star this property tabling member constituency Gravesham more like this
star this property tabling member printed
Adam Holloway more like this
star this property title House of Commons Tabled Parliamentary Question 2017/19 280996 more like this
star this property type
WrittenParliamentaryQuestion
star this property uin 280996 more like this
star this property version 1 more like this
star this property written parliamentary question type Ordinary more like this
star this property answer
answer
unstar this property answer text <p>While post vaccine rash and fever is generally mild, distinguishing from wild-type measles is not based on clinical examination, rather it is based on a combination of laboratory analysis, information on the timing of vaccine and epidemiological information. The national measles guidelines describe the management and investigation of suspected cases of measles, and is available to view at the following link:</p><p><a href="https://www.gov.uk/government/publications/national-measles-guidelines" target="_blank">https://www.gov.uk/government/publications/national-measles-guidelines</a></p><p>Statistics on confirmed measles cases are reported by vaccination status and are available at the following link:</p><p><a href="https://www.gov.uk/government/publications/measles-mumps-and-rubella-lab-confirmed-cases-in-england-2019" target="_blank">https://www.gov.uk/government/publications/measles-mumps-and-rubella-lab-confirmed-cases-in-england-2019</a></p><p> </p><p> </p> more like this
star this property creator
1522
star this property label Biography information for Adam Holloway more like this
star this property publisher
25259
star this property pref label House of Commons more like this
star this property tabling member
1522
unstar this property label Biography information for Adam Holloway more like this
1141364
star this property human indexable true more like this
star this property published true more like this
star this property registered interest false more like this
star this property answer date less than 2019-07-25more like thismore than 2019-07-25
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property date tabled less than 2019-07-23more like thismore than 2019-07-23
star this property ddp created less than 2019-07-23T16:59:22.183Zmore like thismore than 2019-07-23T16:59:22.183Z
star this property answering body
Department of Health and Social Care more like this
star this property question status Tabled more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property ddp modified
less than 2019-07-23T17:09:28.792Zmore like thismore than 2019-07-23T17:09:28.792Z
less than 2019-08-05T12:04:04.481Zmore like thismore than 2019-08-05T12:04:04.481Z
star this property hansard heading MMR Vaccine: Side Effects more like this
star this property house id 1 more like this
star this property identifier 280997 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property parliament number 57 more like this
star this property question first answered
less than 2019-08-05T11:34:01.177Zmore like thismore than 2019-08-05T11:34:01.177Z
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that (a) body inclusion encephalitis and (b) other adverse events experienced after a measles vaccine are identified in a timely way by healthcare professionals. more like this
star this property session
2017/19 more like this
star this property session number 1 more like this
star this property tabling member constituency Gravesham more like this
star this property tabling member printed
Adam Holloway more like this
star this property title House of Commons Tabled Parliamentary Question 2017/19 280997 more like this
star this property type
WrittenParliamentaryQuestion
star this property uin 280997 more like this
star this property version 1 more like this
star this property written parliamentary question type Ordinary more like this
star this property answer
answer
unstar this property answer text <p>The safety of all the United Kingdom’s vaccination programmes is of paramount importance. Any serious side effects are extremely rare, and the large majority of side effects are mild and transient, such as sore arms, headaches and tiredness. We would recommend that all eligible children are vaccinated, as any potential risk of side effects is far outweighed by the benefits of vaccination.</p><p>Healthcare professionals have access to a range of materials, such as ‘Immunisation against infectious disease: the green book’ and Patient Group Directions to support their decision-making in the case of any suspected adverse effects.</p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) operates the ‘Yellow Card Scheme’, which is vital in helping the MHRA monitor the safety of all healthcare products in the UK. This system allows for reporting of any potential adverse events for all medicines, including vaccines, with guidance for healthcare professionals, patients and the public on how to use the scheme.</p><p>In addition, Public Health England (PHE) offers diagnostic services for suspected cases of encephalitis, which is a notifiable condition. Under statutory duty, cases must be reported by healthcare professionals to PHE’s local Health Protection Teams. This can be viewed at the following link:</p><p><a href="https://www.gov.uk/government/collections/notifications-of-infectious-diseases-noids" target="_blank">https://www.gov.uk/government/collections/notifications-of-infectious-diseases-noids</a></p>
star this property creator
1522
star this property label Biography information for Adam Holloway more like this
star this property publisher
25259
star this property pref label House of Commons more like this
star this property tabling member
1522
unstar this property label Biography information for Adam Holloway more like this
1141380
star this property human indexable true more like this
star this property published true more like this
star this property registered interest false more like this
star this property answer date less than 2019-07-25more like thismore than 2019-07-25
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property date tabled less than 2019-07-23more like thismore than 2019-07-23
star this property ddp created less than 2019-07-23T17:00:00.257Zmore like thismore than 2019-07-23T17:00:00.257Z
star this property answering body
Department of Health and Social Care more like this
star this property question status Tabled more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property ddp modified
less than 2019-07-23T17:10:05.284Zmore like thismore than 2019-07-23T17:10:05.284Z
less than 2019-07-25T17:07:10.933Zmore like thismore than 2019-07-25T17:07:10.933Z
star this property hansard heading MMR Vaccine: Safety more like this
star this property house id 1 more like this
star this property identifier 280998 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property parliament number 57 more like this
star this property question first answered
less than 2019-07-25T16:35:38.84Zmore like thismore than 2019-07-25T16:35:38.84Z
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to maintain and improve pharmacovigilance in relation to the MMR vaccine. more like this
star this property session
2017/19 more like this
star this property session number 1 more like this
star this property tabling member constituency Gravesham more like this
star this property tabling member printed
Adam Holloway more like this
star this property title House of Commons Tabled Parliamentary Question 2017/19 280998 more like this
star this property type
WrittenParliamentaryQuestion
star this property uin 280998 more like this
star this property version 1 more like this
star this property written parliamentary question type Ordinary more like this
star this property answer
answer
unstar this property answer text <p>As with all vaccines and medicines, the safety of the Measles, Mumps and Rubella (MMR) vaccine remains under continual review by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA uses all available sources of evidence in pharmacovigilance, including regular review of suspected adverse reactions submitted through the Yellow Card Scheme, data from clinical and epidemiological studies, the medical literature and information from pharmaceutical companies and other worldwide regulatory authorities. The MHRA’s processes and data analysis systems are regularly evaluated to ensure optimal performance in monitoring the safety of vaccines and medicines.</p><p>The balance of benefits and risks of MMR vaccine remains overwhelmingly favourable.</p> more like this
star this property creator
1522
star this property label Biography information for Adam Holloway more like this
star this property publisher
25259
star this property pref label House of Commons more like this
star this property tabling member
1522
unstar this property label Biography information for Adam Holloway more like this
1141381
star this property human indexable true more like this
star this property published true more like this
star this property registered interest false more like this
star this property answer date less than 2019-07-25more like thismore than 2019-07-25
star this property date less than 2019-07-23more like thismore than 2019-07-23
star this property date tabled less than 2019-07-23more like thismore than 2019-07-23
star this property ddp created less than 2019-07-23T17:00:03.223Zmore like thismore than 2019-07-23T17:00:03.223Z
star this property answering body
Department of Health and Social Care more like this
star this property question status Tabled more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property ddp modified
less than 2019-07-23T17:10:07.916Zmore like thismore than 2019-07-23T17:10:07.916Z
less than 2019-07-25T17:10:01.910Zmore like thismore than 2019-07-25T17:10:01.910Z
star this property hansard heading MMR Vaccine more like this
star this property house id 1 more like this
star this property identifier 280999 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property parliament number 57 more like this
star this property question first answered
less than 2019-07-25T16:38:57.347Zmore like thismore than 2019-07-25T16:38:57.347Z
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure (a) transparency and (b) accountability in the process of manufacturing the MMR vaccine. more like this
star this property session
2017/19 more like this
star this property session number 1 more like this
star this property tabling member constituency Gravesham more like this
star this property tabling member printed
Adam Holloway more like this
star this property title House of Commons Tabled Parliamentary Question 2017/19 280999 more like this
star this property type
WrittenParliamentaryQuestion
star this property uin 280999 more like this
star this property version 1 more like this
star this property written parliamentary question type Ordinary more like this
star this property answer
answer
unstar this property answer text <p>Two Measles, Mumps and Rubella (MMR) vaccines are licensed for use in the United Kingdom: M-M-RVaxPro and Priorix. Both vaccines are on the National Health Service’s routine immunisation schedule. The quality, safety and efficacy of both M-M-RVaxPro and Priorix have been evaluated before they were given a Marketing Authorisation in Europe, and the Marketing Authorisation Holder for each vaccines is legally required to submit periodic safety update reports to the regulator, which are documents intended to provide an evaluation of the risk-benefit balance of a medicinal product at defined time points after its authorisation. The sites at which the products are manufactured are also required to undergo periodic inspections to ensure that they comply with Good Manufacturing Practices. Each batch of vaccines is tested by an official medicines control laboratory (OMCL). OMCL testing is independent of and in addition to the manufacturer’s testing. These procedures ensure that the MMR vaccines available in the UK are safe and efficacious and that the manufacturers/Marketing Authorisation holders are held accountable for their products.</p><p>A European Public Assessment Report (EPAR) for M-M-RVaxPro is available at the following link:</p><p><a href="https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf" target="_blank">https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf</a></p><p>Priorix was approved before public assessment reports were a requirement. The EPAR for M-M-RVaxPro contains a general summary of the manufacturing information that was provided during the assessment process; however, the specific details of the manufacturing process are confidential.</p>
star this property creator
1522
star this property label Biography information for Adam Holloway more like this
star this property publisher
25259
star this property pref label House of Commons more like this
star this property tabling member
1522
unstar this property label Biography information for Adam Holloway more like this